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Urothelial carcinoma (UC) is a common disease causing significant morbidity and mortality as well as 
considerable costs for health systems. Extensive aberrant methylation of DNA is broadly documented 
in early UC, contributing to genetic instability, altered gene expression and tumor progression. 
However the triggers initiating aberrant methylation are unknown. Recently we discovered that 
several genes encoding key enzymes of methyl group and polyamine metabolism, including 
Ornithine Decarboxylase 1 (ODC1), are affected by DNA methylation in early stage UC. In this study, 
we investigated the hypothesis that these epigenetic alterations act in a feed-forward fashion to 
promote aberrant DNA methylation in UC. We demonstrate that siRNA-mediated knockdown of ODC1 
expression elicits genome-wide LINE-1 demethylation, induction of LINE-1 transcripts and double-
strand DNA breaks and decreases viability in primary cultured uroepithelial cells. Similarly, following 
siRNA-mediated knockdown of ODC1, UC cells undergo double-strand DNA breaks and apoptosis. 
Collectively, our findings provide evidence that ODC1 gene hypermethylation could be a starting point 
for the onset of genome-wide epigenetic aberrations in urothelial carcinogenesis. Furthermore, LINE-1 
induction enabled by ODC1 interference provides a new experimental model to study mechanisms and 
consequences of LINE-1 activation in the etiology and progression of UC as well as presumably other 
cancers.
Urothelial carcinoma (UC), the most common cancer of the urinary bladder, is a frequent disease with yearly 
549,393 new cases and 199,922 deaths worldwide1. Relapse rates of 30–70% and rates of progression at 10–30% 
for high-grade tumors present a serious health care challenge and impose enormous financial burdens on the 
health care systems2. In particular, UC that have invaded the muscle-layers of the bladder are highly lethal.
Tobacco smoking is thought to contribute to 50% of all UC cases as a risk factor3. Aromatic amines such as 
2-naphthylamin and polycyclic aromatic hydrocarbons in cigarette smoke cause mutations in key cancer-related 
genes by forming DNA adducts4. Accordingly, exposure to tobacco smoke alone is sufficient to induce 
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transformation in urinary tract epithelial cells, which is moreover accompanied by aberrant DNA methylation5. 
Therefore urologists are advised to inform patients on the factors causing UC and strongly counsel them to stop 
smoking6.
The methylome which consists of all methylated cytosine-guanosine (CpG) dinucleotides, forms an elaborate, 
plastic and cell-type specific pattern in mammalian cells. It supports genome organization, gene regulation and 
preserves genome integrity by repressing transposable genetic elements7. Importantly, the methylome is influ-
enced by exogenous factors.
Aberrant changes of the genome-wide DNA methylation pattern are broadly-documented and have long been 
established as an early event in the development of UC8–10. Focal DNA methylation changes affect among others 
tumor suppressor genes11 and may therefore causally contribute to the development and progression of UC. 
Global DNA hypomethylation, a genome-wide decrease in methylcytosine, occurs concomitantly, affecting in 
particular endogenous retroviruses (HERVs) and retrotransposons (SINEs and LINEs) and may result in their 
transcriptional reactivation12. In particular, substantial global LINE-1 DNA hypomethylation in bladder cancer 
is accompanied by a shift toward expression of full-length LINE-1 elements13.
Expression of retrotransposons can damage the genome14. LINE-1 RNA and protein overexpression, e.g., have 
been linked to apoptosis, DNA damage and repair, tumor progression, cellular plasticity, and stress response14. 
As part of the activated LINE-1 target-primed reverse transcription (TPRT) retrotransposition mechanism, the 
endonuclease activity of the LINE-1 ORF2 protein generates a double-strand DNA break that recruits repair 
proteins to the retrotransposon insertion site. Thus, DNA damage caused by overexpression of ORF2 proteins 
may induce genotoxic stress and apoptosis14. It has been proposed that LINE-1 hypomethylation and activation 
may play a causative role in urothelial carcinogenesis by inducing genetic instability which accompanies cancer 
progression, especially in high-stage and high-grade cancer15. However, non-invasive and early invasive papillary 
transitional cell carcinomas of stages pTa and pT1, respectively, already present a plethora of genetic aberrations 
including losses and gains of their genetic material16,17, with an increase of genomic instability when tumors 
progress further17.
Despite clear evidence for the involvement of an abnormal methylome and particularly LINE-1 hypometh-
ylation in urothelial carcinogenesis it remains unknown how this process is initiated. To date, suitable in vitro 
models to investigate this issue are lacking, but are urgently required to understand both, how these epigenetic 
alterations are caused and how they promote cancer progression.
Recently, we have provided evidence that aberrant epigenetic regulation of key enzymes of methyl group 
and polyamine metabolism could be involved in establishing aberrant methylomes in UC18. Here we show for 
the first time that experimental downregulation of the gene encoding a key enzyme of polyamine biosynthesis, 
ornithine decarboxylase (ODC1), results in global LINE-1 hypomethylation, induction of LINE-1 transcripts, 
double-strand DNA breaks in primary cultured uroepithelial cells and the immortalized uroepithelial cell line 
HBLAK. Similarly, urothelial carcinoma cells undergo apoptosis after having acquired double-strand DNA breaks 
following ODC1 interference by siRNA.
Results
ODC1 RNA interference rapidly induces LINE-1 hypomethylation and LINE-1 transcripts in pri-
mary cultures of uroepithelial cells. Recently, during a genome-wide screening of pTa and pT1 urothelial 
cancer tissue samples for altered DNA methylation, we observed distinct hypermethylation at the promoters of 
key genes of methyl group and polyamine metabolism pathways18. Disturbances of these key enzymes are known 
to lead to grave imbalances in the delicate intracellular SAM:SAH ratio resulting in genome wide DNA meth-
ylation alterations, including genome-wide LINE-1 hypomethylation19–21. Therefore, we hypothesized that our 
observation may provide an explanation for the mechanisms involved in hypomethylation of LINE-1 retrotrans-
posons, a hallmark of early urothelial cancer.
First, we analyzed the LINE-1 methylation status of 8 pTa and 6 pT1 early urothelial cancer tissue specimens 
in which we had previously observed ODC1 promoter hypermethylation18, using idiolocal normalized real-time 
Methylation Specific PCR (IDLN-MSP)22. This improved method allows for a reliable comparison of LINE-1 
methylation in normal and tumor tissue specimens, despite genetic heterogeneity and copy number alterations 
present in early urothelial cancer16,17. We observed LINE-1 hypomethylation in 6 pTa and 6 pT1 urothelial carci-
noma samples compared to 3 samples of healthy urothelium and 4 samples of tumor-adjacent uroepithelial tissue. 
Two pTa low grade tumor samples showed no hypomethylation (Fig. 1).
Next, we down-regulated ODC1 gene expression by RNAi in the immortalized uroepithelial cell line HBLAK. 
This cell line developed spontaneously from a primary culture of uroepithelial cells and has a stable karyotype 
with few chromosomal changes23. In addition, we applied this approach to primary, short-term cultured uroep-
ithelial cell cultures, in order to exclude genetic and epigenetic alterations accumulating during prolonged cell 
cultivation as confounding factors. In both cell models, we achieved a clear repression of ODC1 mRNA after 24 h 
of ODC1 targeting by RNAi to <20% in HBLAK and <40% in primary uroepithelial cells (Fig. 2, suppl. Figure 1). 
ODC1 is tightly regulated at the protein level by multiple mechanisms which control its very rapid turnover24, 
implying that its transcriptional downregulation would lead to diminished enzyme activity within the cell. In 
addition, in both systems we detected a decrease in LINE-1 methylation, of 20% in HBLAK and of up to 50% in 
primary uroepithelial cell cultures after the first 24 h of ODC1 downregulation. Consequently, LINE-1 transcripts 
increased after 48 h, with a 4-fold increase in HBLAK cells and a 2-fold increase in primary uroepithelial cell 
cultures. The increase in LINE-1 transcripts was paralleled by a decrease in DNA methylation of the LINE-1 pro-
moter as demonstrated by bisulfite genomic sequencing of DNA from the same primary uroepithelial cell culture. 
DNA methylation in the ODC1 RNAi-treated cells was 35.8% compared to 63.5% in non-targeting RNAi-treated 
cells (Fig. 3). Thus, repression of ODC1 by RNAi rapidly results in LINE-1 hypomethylation and an increase of 
LINE-1 transcripts.
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ODC1 RNA interference inhibits cell growth and induces p21 transcripts in uroepithelial cells 
as well as in UC cells. Deregulated expression of retrotransposons can damage the genome. In particular, 
the endonuclease activity of the LINE-1 ORF2 protein is able to generate double-strand DNA breaks, which can 
ultimately lead to apoptosis14, thus decreasing the number of viable cells.
Therefore we investigated cell numbers after ODC1 RNA interference. We observed that after 24 h of RNAi 
treatment, uroepithelial cells undergo a substantial inhibition of cell growth (Fig. 4A). Interestingly, the same 
effect was observed as well in urothelial carcinoma cells (HT1376) (Fig. 4A). Expression of the cell cycle inhib-
itor p21 (WAF1/CIP1; CDKN1A) is induced by DNA damage25 leading to its binding and inhibition of cyclin 
dependent kinases CDK1 and CDK2 and inhibition of cell cycle progression26. This delay in the cell cycle enables 
the repair of damaged DNA. Concomitantly p21 exerts anti-apoptotic activities25, prominently by binding to and 
inhibiting caspase 3, a crucial executor of genotoxic stress-induced apoptosis27. Therefore, p21-deficient cells 
are more prone to undergo apoptosis after DNA damage25. Interestingly, data from TCGA suggest that p21 is 
significantly frequently mutated in bladder cancer25, a. o., the HT1376 UC cell line used here does not express p21 
protein due to a frame shift mutation28.
Knockdown of ODC1 by RNA interference diminished the number of cells in a uroepithelial cell culture by 
approximately 50% after 24 h. This effect persisted after 48 and 72 h of RNAi treatment (Fig. 4A). The decrease 
in cell numbers was accompanied by a 2-fold increase of p21 transcripts at all time points in siRNA-treated cells 
compared to control siRNA-treated cells, in which p21 mRNA notably increased over time (Fig. 4B).
In HT1376 UC cells a 4-fold increase occurs after 48 h of treatment that extended to an 8-fold increase after 
72 h (Fig. 4B).
ODC1 RNA interference results in DNA double-strand breaks in uroepithelial cells and urothe-
lial cancer cells and in apoptosis in urothelial cancer cells. To investigate whether DNA damage and 
apoptosis may underlie the observed decrease in cellular viability following ODC1 downregulation, we assayed 
γH2AX, an established biomarker of DNA damage response at DNA double-strand breaks29. Consistently, 
we detected an increase of γH2AX in ODC1 RNAi-treated uroepithelial cells after 72 h. Similar changes were 
observed in HT1376 urothelial cancer cells. Higher γH2AX levels were also detected in the supernatant of 
siRNA-treated cells compared to the controls (Fig. 5A). This is explained by loss of cell membrane integrity in 
apoptosis resulting in the release of the cellular contents, including chromatin into the environment30,31.
Finally, we investigated whether cell death indeed occurred by apoptosis by assaying the active form of caspase 
3/730. After 72 h of ODC1 RNAi treatment we detected more activated caspase 3/7 activity in the treated cancer 
cells than in the untreated HT1376 cells (Fig. 5B).
Discussion
There is strong evidence that chemical carcinogens are involved in bladder carcinogenesis and induce mutations. 
However, it remains unclear which genes are affected first and constitute the crucial hits initiating the various 
subtypes of the disease. It is moreover unknown whether epigenetic alterations precede, accompany or follow 
genetic changes. Elucidating the first steps in bladder carcinogenesis could facilitate prevention and early diag-
nosis, and thereby lead to an improved prognosis and lower mortality rates. Previously, we showed that ODC1 























Figure 1. Relative quantification of LINE-1 methylation in early UC tissue specimens. LINE-1 methylation 
was measured by real time IDLN-MSPCR in four healthy-(hU), in three tumor adjacent uroepithelial (adjT), in 
eight pTa and in six pT1 UC tissue specimens.
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ODC1 is the rate-limiting enzyme of polyamine biosynthesis and is expressed in virtually all tissues. It catalyzes 
the decarboxylation of ornithine to putrescine which subsequently is converted to the polyamines spermidine and 
spermine, by addition of propylamine groups from decarboxylated S-adenosylmethionine (dcSAM). Spermidine 
and spermin bind to and stabilize nucleic acids and nucleoprotein structures in the cell. In particular, they stabi-
lize DNA and exert protection against cellular stress, for example, induced by DNA damaging agents32. Increased 
polyamine biosynthesis in cancer is considered important for tumor growth and survival due to increased meta-
bolic needs33 and constitutes a critical factor in determining sensitivity to folate depletion34. Activation of ODC1 
and consequently increased concentrations of polyamines are related to tumor promotion and progression in 
many cancer entities. For instance ODC1 overexpression has been reported for breast cancer, lung cancer, colon 
cancer, prostate cancer, pancreatic cancer, gliomas and others33. Difluoromethylornithine (DFMO), a potent 
irreversible inhibitor of ODC, exerts cytostatic activity by diminishing levels of folate-dependent metabolites, 
including S-adenosylmethionine (SAM) and thymidine pools in intestinal tumors and human colorectal cancer 
cells35 (compare suppl. Figure 2). Antitumor activity of DFMO has been supported by clinical trials on glio-
mas, nonmelanoma skin cancer, colon cancer and neuroblastoma33. Noteworthy, normal intestinal epithelial cells 
Figure 2. ODC1 RNA interference in uroepithelial cells. ODC1 gene expression (A), LINE-1 methylation (B), 
LINE-1 expression (C) in HBLAK, an immortalized uroepithelial cell line (graphs on the left) and in short-
term cultured primary uroepithelial cells (graphs on the right) after downregulation of ODC1 by RNAi over the 
indicated times.
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arrest in response to DFMO at the G1 phase of the cell cycle likely due to upregulation of p2136. Likewise, human 
melanoma cells develop a senescence-like phenotype following DFMO treatment37.
ODC1 is upregulated in many cancer types, as evidenced e.g. in the comprehensive pan-cancer “The Cancer 
Genome Atlas” TCGA expression data (suppl. Figure 3). However, ODC1 mRNA expression in bladder cancer is 
lower than in normal bladder tissues and among the lowest of any cancer type38 (suppl. Figure 3). In accord with 
Figure 3. Bisulfite genomic sequencing of the LINE-1 promoter region in primary uroepithelial cells before 
and after ODC1 RNA interference. Detailed analyses of LINE-1 promoter CpG methylation status of primary 
uroepithelial cells (A) and of the same uroepithelial cells after 72 h of treatment with ODC1 RNAi (B). Black, 
white and grey circles stand for methylated, unmethylated and undefined CpG dinucleotides, respectiely. The 
graph at the top of the figure depicts a schematic representation of a full-length LINE-1 retroelement with the 
proportional distribution of all CpG dinucleotides (short ertical strokes) and the open reading frames 1 and 2 
(ORF1/2). The CpG rich region analyzed by bisulfite genomic sequencing is highlighted by a square bracket.
Figure 4. Cell growth and relative p21 expression in ODC1 RNAi treated uroepithelial cells and urothelial 
cancer cells. Cell numbers (A) and relative p21 expression (B) were measured after treatment of cultured 
uroepithelial cells (graphs on the left) and HT1376 UC cells (graphs on the right) by ODC1 RNAi for 24, 48 and 
72 h, as depicted.
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these findings, in an investigation of patients with various genitourinary cancers, spermidine (20%) and sper-
mine (20%) were diminished especially in the urine of bladder patients compared to probands without bladder 
cancer39.
DNA methylation is established as a mechanism regulating ODC1 gene expression. In early studies a positive 
correlation between ODC1 gene hypomethylation and expression was reported40 and experimental methylation 
of the ODC1 gene abolished its expression41. Furthermore aberrant ODC1 methylation has been reported in 
malignant cells42. Recently, we demonstrated that the 5′-regulatory region of ODC1 is hypermethylated in most 
analyzed early UC (pTa/pT1) specimens and that its promoter activity can be efficiently repressed by DNA meth-
ylation18. Thus we concluded that dense DNA methylation, epigenetically impairs ODC1 expression. ODC1 is 
tightly linked to methyl group metabolism since interference with its enzymatic activity results in accumulation 
of SAH and decarboxylated S-adenosylmethionine (dcSAM), potent competitive inhibitors of methylation reac-
tions that cause genome-wide DNA demethylation, as shown e.g. in human oral cancer cells20. Thus, hypermeth-
ylation of ODC1 impairing ODC1 gene expression in early urothelial cancer could act in a feed-forward fashion to 
promote further changes in methylation patterns, global DNA and LINE-1 hypomethylation. LINE-1 hypometh-
ylation and activation which are established as widespread and early events in urothelial carcinogenesis would be 
facilitated by ODC1 repression. LINE-1 expression in turn is thought to contribute to genetic instability during 
tumor progression. Mimicking ODC1 gene repression in early stage UC and in uroepithelial cells by RNA inter-
ference in vitro indeed induced a comparable process as it elicited LINE-1 demethylation, LINE-1 transcriptional 
Figure 5. Detection of γH2Ax in uroepithelial and urothelial cancer cells (UC) and Caspase 3/7 actiity in UC 
after 72 h of ODC1 downregulation by RNAi. γH2Ax was determined by Western Blot analysis in uroepithelial 
cells, urothelial cancer cells and their cell-free culture medium supernatants before and after treatment with 
ODC1 RNAi for 72 h (A) (two analyses shown). Caspase 3/7 actiity was determined in HT1376 after the same 
treatment (B).
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activation and DNA double-strand breaks. This resulted in increased p21 expression and proliferation inhibition 
indicating the activation of cellular checkpoints. Consequently, diminished proliferation was observed in normal 
uroepithelial cells, whereas UC cells underwent apoptosis following interference with ODC1. This suggests that 
normal urothelial cells can respond to imbalances in methyl-group and polyamine metabolism as well as DNA 
damage by appropriate mechanisms, e.g. checkpoint activation, which UC cells lack. Nevertheless, if ODC1 defi-
ciency is a frequent phenomenon in urothelial carcinogenesis, later on in the course of tumor progression, tumor 
cells need to adapt to it, counter or overcome it by still unknown mechanisms, which may include the impedi-
ment of checkpoints characteristic of advanced bladder cancers. Obviously, this difference in response to ODC1 
repression or inhibition may provide a therapeutic window, which deserves further exploration.
Interference with ODC1, a key gene of polyamine metabolism, results in global demethylation and genetic 
instability. Further, we see that this may be responsible for the induction of the carcinogenesis process. With 
this model in hand, future research will be able to address whether this apparently crucial interference with 
polyamine group metabolism contributes to tumorigenesis. In addition, we will perform SAM/SAH ratio quan-
tification of urinary S-adenosylmethionine and S-adenosylhomocysteine by stable-isotope-dilution liquid 
chromatography-mass spectrometry43 from UC patients and healthy probands to estimate its value for early 
detection of UC. In addition, using the same model we will explore the role of other methyl group metabo-
lism genes that we found concomitantly hypermethylated with ODC1 in urothelial carcinoma, like AHCY and 
AHCYL218. We therefore hypothesize that further genes of methyl group metabolism in addition to ODC1 
contribute to disturbances of the methylome and thereby promote tumor progression. We are very eager to see 
whether the genetic integrity of these key genes mirrors DNA adduction caused by chemical carcinogens. The 
disruption of the genetic integrity of a gene can lead to promoter methylation and constitutive epigenetic gene 
silencing.
One additional aim is to develop a reliable non-invasive urinary UC diagnosis based on a combination of 
methylation biomarkers, e.g. LINE-1 hypomethylation and/or hypermethylated key genes, e.g. ODC1, AHCY, 
providing an early non-invasive detection method for the disease with high sensitivity and specificity.
Finally, LINE-1 hypomethylation and activation is a common phenomenon in many different cancers12,44. To 
our knowledge until now there was no approach available to deliberately induce this important epigenetic altera-
tion in normal epithelial cells. Models analogous to ours may therefore yield insights in the relationship between 
epigenetic alterations and carcinogenesis in other cancer types as well. Our results highlight the question to which 
extent, presumably temporary, disturbances in methyl-group metabolism and polyamine biosynthesis contribute 
to LINE-1 hypomethylation in other cancers12,44. If so, the ODC1 RNAi approach we describe here may be suita-
ble to study the functional consequences of LINE-1 hypomethylation and its role in the carcinogenesis process of 
many other cancer entities as well.
Methods
Tissue samples. Cell lines and cell cultures. Cultivation of primary uroepithelial cells and HBLAK cells 
was performed as described by Swiatkowski et al. and Hoffmann et al.45,46. The UC cell line HT1376 was isolated 
from a high grade urothelial cancer of a 58 years old female patient47 and was kindly provided by the DSMZ 
(Braunschweig, Germany).
Preparation of DNA from formalin-fixed, paraffin-embedded (FFPE) tissue samples. All methods were carried 
out in accordance with relevant guidelines and regulations. We confirm that the experimental protocols were 
approved and informed consent was obtained from all participants. An appropriate ethics vote was granted by the 
Kantonale Ethikkommission Zürich on 22.02.2013, Ref. Nr. KEK-ZH-Nr 2012–0352. All samples were prepared 
as previously described in detail18.
The tissue samples were pathologically reviewed, microdissected and prepared as previously described18. In 
Fig. 1, from left to right, all pTa samples but sample number 4 (high grade) are low grade and all pT1 samples but 
sample number 1 (low grade) are high grade UC samples.
Relative Quantification of LINE-1 methylation in UC and reference samples by real-time MSP. Real time 
Methylation-Specific PCR of differentially methylated LINE-1 promoter regions was performed as follows: 
Bisulfite-converted DNA of the tissue samples served as template for amplification of methylated LINE-1 
sequences in a normalized real time MSP approach for genetic imbalanced DNA specimens as described22. The 
primers used are listed in Table 1. The amplification conditions were denaturation at 95 °C for 10 min, followed by 
40 cycles of 95 °C for 30 s, Tm for 40 s and 72 °C for 15 s.
ODC1 RNA interference. 400.000 (primary urothelium) or 50.000 (HT1376) cells per well were seeded in 
6-well plates (Sarstedt, Nümbrecht, Germany). 40 pmol of siRNA (2 µl) (Human ODC1 (4953) siRNA, M-006668-






sL1met 5′-GCGCGAGTCGAAGTAGGGC-3′ 193 61
asL1met 5′-CTCCGACCAAATATAAAATATAATCTCG-3′
sL1control 5′-AGGTTTTATTTTTGGGGGTAGGGTATA-3′ 207 58
asL1control 5′-CCCCTACTAAAAAATACCTCCCAATTAAAC-3′
Table 1. Primers for IDLN-MSP.
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with 248 µl Opti-MEM (1×) medium (Gibco). 5 µl of Lipofectamine 2000 (Dharmacon) were mixed with 245 µl 
Opti-MEM (1×) medium (Gibco). All mixes were incubated for 5 mins at RT. Then every siRNA mix was mixed 
together with the Lipofectamine mix and incubated for additional 20 mins at RT. Afterwards, 500 µl of the 
final mix was added to each well. Cells were kept in the incubator at 37 °C for 24 h, 95% humidity and 5% CO2. 
Retransfection with siRNA was performed every 24 h for three times.
Bisulfite genomic sequencing. Bisulfite sequencing was performed following bisulfite conversion with the 
EpiTec Kit (Qiagen, Hilden, Germany) as described48–50. PCR primers for specific amplification of LINE-1 pro-
moter sequences are listed in Table 2. The amplification conditions were denaturation at 95 °C for 13 min, followed 
by 35 cycles of 95 °C for 50 s, 51 °C for 45 s, and 72 °C for 30 s. We used 10–20 ng of bisulfite converted DNA, x µl 
of a 200 µM dNTP Mix solution (Promega), 10 pm of each primer and 1.5 units of HotStarTaq DNA Polymerase 
(Qiagen) per reaction. The amplification product was 436 bp. The TA Cloning Kit (Invitrogen) was used for cloning 
of the amplification products according to the manufacturer’s instructions. Sequence evaluation was performed with 
the BigDye Terminator Cycle Sequencing Kit (Applied Biosystems) on a DNA analyzer 3700 (Applied Biosystems) 
using the M13-as primer. On average 30 clones were sequenced to obtain the methylation profile of one sample. All 
sequences were aligned using CLUSTLW from the Kyoto University Bioinformatics Center on http://www.genome.
jp/tools/clustalw/ and all methylated CpGs were manually counted for every single CpG position.
RNA preparation, cDNA synthesis, and real-time PCR. RNA was prepared using the RNeasy Mini 
Kit (Qiagen) according to the manufacturer’s instructions. First-strand cDNA synthesis was performed from 
1.5 µg RNA by reverse transcription using oligo(dT) (Promega) and Moloney murine leukemia virus reverse 
transcriptase (Promega) in a volume of 50 µL at 42 °C for 1 h. Real-time PCR was carried out with SYBR Green 
PCR Mastermix (Applied Biosystems) using 25 ng template cDNA. All reactions were run in triplicates on a 
StepOnePlus System (Applied Biosystems, Foster City, CA). Standard curves were generated using StepOne soft-
ware v2.1 (Applied Biosystems). Relative changes in gene expression were calculated following the ∆∆Ct-method 
with glyceraldehyde-3-phosphate dehydrogenase (GAPDH) mRNA as a standard. Primers were designed after 
excluding pseudogenes or other closely related genomic sequences which could interfere with specific amplifica-
tion by amplicon and primer sequences comparison in BLAT sequence data base (https://genome.ucsc.edu/FAQ/
FAQblat.html) Table 3.
Determination of cell numbers. After siRNA treatment the cell numbers were determined using a 
Neubauer counting chamber (Bürker, Friedrichsdorf, Germany). 10 µl of each cell suspension was mixed with 
10 µl trypan blue (0.4%) (Gibco) and pipetted into the chamber. Four large corner squares were counted under 
an inverse laboratory microscope (Leica). Cell numbers were calculated with the following formula: cell/ml = 
average of the number of cells counted over all squares × chamber factor × dilution factor.
Western blot. Primary uroepithelial cells and HT1376 urothelial cancer cells and NCCIT teratocarcinoma 
cells were lysed in lysis buffer containing 5 M NaCl, 1% NP-40, 0.5% DOC, 0.1% SDS, 1 mM EDTA, 50 mM 
Tris, pH 8.0, and freshly added 10 µL/mL protease inhibitor (Sigma, Munich, Germany). 15 µg of protein was 
resolved in a 12% sodium dodecyl sulfate-PAGE gel and transferred onto Immobilon-P membrane (Millipore). 
Membranes were probed with primary antibody against Phospho-Histone H2A.X (Ser139) (20E3, Rabbit mAb, 
Cell Signaling, Frankfurt, Germany) and β-Actin (8H10D10 Mouse mAb, Cell Signaling, Frankfurt, Germany) 
at 4 °C overnight, washed with 0.1% Tween-20 in Tris-buffered saline, and incubated with secondary antibody 
conjugated with horseradish peroxidase. The signals were visualized with enhanced luminescence (WesternBright 




s1LINEkonv1Ampl 5′-GGTTTATTTTATTAGGGAGTGTTAG-3′ 436 51
as1LINEkonv1Ampl 5′-ACAAAAACAAACAAACCTCC-3′







s1GAPDHmrna 5′-CATGACAACTTTGGTATCGTGGA-3′ 381 62
as1GAPDHmrna 5′-GTGGGTGTCGCTGTTGAAGTC-3′
s1ODC1mrna 5′-CCGCTCGAGCGGATAAGTAGGGAGCGGCGTG-3′ 276 54
as1ODC1mrna 5′-ATCATGGCGACCCTACTCTTAC-3′
s1LINEmRNA 5′-TGGAATAGGTGTGGTGTGGTGCT-3′ 246 61
as1LINEmRNA 5′-TCACTCAGGACAGCCCAGACG-3'
sp21mrna 5′-GGAAGACCATGTGGACCTGT-3′ 146 55
asp21mrna 5′-GGCGTTTGGAGTGGTAGAAA-3′
Table 3. Primers for real-time PCR.
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Apoptosis detection. Apoptosis assay was performed using the ImageIT Live Red Caspase-3 and -7 
Detection Kit (Thermo Fisher Scientific, Ort, Land) according to the manufacturer's instructions. In brief, cells 
were seeded in a 12 well plate (Sarstedt, Ort, Land). After treatment with siRNA for 72 h, the cells were washed 
with PBS and incubated with a 30-fold dilution of the provided FLICA reagent for 60 min at 37 °C for 24 h, 95% 
humidity and 5% CO2. After this incubation the cells were washed again with PBS and nuclei were stained with 
HOECHST 33342 (Thermo Fisher Scientific). To remove the Hoechst solution two additional washing steps with 
a 1x dilution of the provided wash buffer were carried out for 5 mins at RT and cells were counted using a fluores-
cent microscope X-Cite Series 120 (Lumen Dynamics, Ort, Land).
Received: 12 July 2019; Accepted: 14 February 2020;
Published: xx xx xxxx
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